Johnson & Johnson
NYSE · JNJHigh QualityEntry review due
$258.45Close
Oct 7, 2026+1.44%last session
Last close.
Oct 7, 2026
Entry rationale
At the dated reference price, the shares demand economics close to our optimistic scenario while leaving substantial downside under ordinary execution. This is a price objection, not an execution blocker; a meaningful discount to our modeled value would change the entry judgment.